Childhood Onset Fluency Disorder
A speech disorder involving frequent problems with the normal fluency and flow of speech.
Wiki Number: W040
Diagnosis: Childhood Onset Developmental Dysfluency
US Patients: 10% Preschoolers
Age Onset: Ages 4-6
Symptoms: Dysfluencies: stuttering, repetition, mistiming, or poor inflection. Time between toddler and pre-school.
Progression: Children may repeat syllables or words as the try to frame sentences correctly. Fluent speech may be delayed.
Medications: None listed – this is normal development, but may be delayed.
Therapies: 10% benefit from a speech therapist/speech language pathologist. They learn how to pronounce speech sounds correctly.
Youtube Video: Childhood Onset Fluency Disorder or Stuttering
Amazon or Library Book: Something To Say About Stuttering
Click the book to link or order from Amazon.
4 CURRENT ARTICLES
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Evaluation of recurrent GNPTAB, GNPTG, and NAGPA variants associated with stutteringby Nandhini Devi Gunasekaran on January 9, 2023
Stuttering is a childhood-onset fluency disorder, intertwined with physiological, emotional, and anxiety factors. The present study was designed to evaluate the recurrence of the reported mutations among three previously implicated (GNPTAB, GNPTG, NAGPA) candidate genes, in persons with stuttering from south India. Mutation screening was performed among 64 probands on 12 specific exons, by Sanger sequencing. A total of 12 variants were identified, which included five nonsynonymous, five...
- Improvement of stuttering after administration of methylphenidate - a case reportby Shahriar SheikhBahaei on March 3, 2022
- Case Report: Deutetrabenazine as an Adjunctive Treatment for Stutteringby Catherine A Ha on November 11, 2021
Childhood-Onset Fluency Disorder (Stuttering) is a neurodevelopmental disorder in which disturbances occur in the normal fluency and time patterning of speech. While the dopamine system has been well-described in its neurophysiology, there currently is no FDA-approved treatment for stuttering. Second-generation antipsychotics, which have been effective in the treatment of schizophrenia and bipolar disorder, act as dopamine D-2 receptor antagonists at the postsynaptic neuron and have been shown...
- Evaluation of an integrated fluency and Acceptance and Commitment Therapy intervention for adolescents and adults who stutter: Participant perspectivesby Alice K Hart on May 23, 2021
CONCLUSION: Findings support the authenticity, acceptability, and social validity of an integrated fluency and psychosocial intervention for stuttering. Findings also highlight the need for consideration of the consumer voice in the management of stuttering disorders, in keeping with person-centred care.